U.S. Markets closed
  • S&P 500

    4,167.59
    +2.93 (+0.07%)
     
  • Dow 30

    34,230.34
    +97.31 (+0.29%)
     
  • Nasdaq

    13,582.42
    -51.08 (-0.37%)
     
  • Russell 2000

    2,241.37
    -6.92 (-0.31%)
     
  • Crude Oil

    65.31
    -0.32 (-0.49%)
     
  • Gold

    1,786.60
    +2.30 (+0.13%)
     
  • Silver

    26.57
    +0.04 (+0.16%)
     
  • EUR/USD

    1.2011
    -0.0004 (-0.0360%)
     
  • 10-Yr Bond

    1.5840
    -0.0080 (-0.50%)
     
  • Vix

    19.15
    -0.33 (-1.69%)
     
  • GBP/USD

    1.3907
    +0.0019 (+0.1335%)
     
  • USD/JPY

    109.2130
    -0.0920 (-0.0842%)
     
  • BTC-USD

    57,043.35
    +3,014.94 (+5.58%)
     
  • CMC Crypto 200

    1,457.26
    +51.96 (+3.70%)
     
  • FTSE 100

    7,039.30
    +116.13 (+1.68%)
     
  • Nikkei 225

    28,812.63
    -241.37 (-0.83%)
     

Glaukos Announces Participation in Oppenheimer Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021, at 3:10 p.m. EDT.

A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018 and most recently, its iStent inject W device in the United States in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005097/en/

Contacts

Chris Lewis
Director, Investor Relations, Corporate Strategy & Development
(949) 481-0510
clewis@glaukos.com